Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 641-649

  Andreana, Lorenzo ^a   Isgrò, Graziella ^a   Marelli, Laura ^a   Davies, Neil ^a   Yu, Dominic ^a   Navalkissoor, Shaunak ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

131 Iodium; 188 Rhenium; 90 Yttrium; Hepatocellular carcinoma; Trans arterial chemo embolisation; Trans arterial embolisation; Trans arterial radio embolization

Indexed keywords

ALBUMIN MICROSPHERE; IODINATED POPPYSEED OIL; IODINE 131; RADIO EMITTER COMPOUND; RADIOISOTOPE; RHENIUM 188; SORAFENIB; UNCLASSIFIED DRUG; YTTRIUM 90;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL PRACTICE; GAMMA RADIATION; HUMAN; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 84861717788     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.004     Document Type: Review

References (73)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917.
3. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011 Mar, 53(3):1020-1022.
4. Makuuchi M., Kokudo N., Arii S., Futagawa S., Kaneko S., Kawasaki S., et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008, 38(1):37-51.
5. Pleguezuelo M., Germani G., Marelli L., Xiruochakis E., Misseri M., Pinelopi M., et al. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008, 2(6):761-784.
6. Dawson L.A., Normolle D., Balter J.M., McGinn C.J., Lawrence T.S., Ten Haken R.K. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002, 53(4):810-821.
7. Lau WY, Lai EC, Leung TW. Current role of selective internal irradiation with Yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. Int J Radiat Oncol Biol Phys. in press.
8. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214.
9. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(3):421-430.
10. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL And mRecist Responses Are Independent Prognostic Factors For Survival In Hepatocellular Cancer Patients Treated With Transarterial Embolisation. J Hepatol. in press.
11. Lewandowski R.J., Kulik L.M., Riaz A., Senthilnathan S., Mulcahy M.F., Ryu R.K., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9(8):1920-1928.
12. Hayashi M., Matsui O., Ueda K., Kawamori Y., Kadoya M., Yoshikawa J., et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999, 172(4):969-976.
13. Goin J.E., Dancey J.E., Roberts C.A., Sickles C.J., Leung D.A., Soulen M.C. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: transcatheter arterial chemoembolization versus yttrium-90 glass microspheres. World J of Nucl Med 2004, 3:49-56.
14. Lui W.Y., Liu R.S., Chiang J.H., Lo J.G., Lai K.H., King K.L., et al. Report of a pilot study of intra-arterial injection of I-131 lipiodol for the treatment of hepatoma. Zhonghua Yi Xue Za Zhi 1990, 46(3):125-133.
15. Kobayashi H., Nakajo M., Shimabukuro K., Shirono K., Sakata H., Oyama T., et al. Possibility of radiotherapy of hepatic cancer by transcatheter arterial embolization with radioactive Lipiodol. Nippon Igaku Hoshasen Gakkai Zasshi 1984, 44(1):96-98.
16. Bretagne J.F., Raoul J.L., Bourguet P., Duvauferrier R., Deugnier Y., Faroux R., et al. Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology 1988, 168(2):547-550.
17. Park C., Choi S.I., Kim H., Yoo H.S., Lee Y.B. Distribution of lipiodol in hepatocellular carcinoma. Liver 1990, 10(2):72-78.
18. Bhattacharya S., Dhillon A.P., Winslet M.C., Davidson B.R., Shukla N., Gupta S.D., et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 1996, 73(7):877-881.
19. Raoul J.L., Bourguet P., Bretagne J.F., Duvauferrier R., Coornaert S., Darnault P., et al. Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988, 168(2):541-545.
20. Nakajo M., Kobayashi H., Shimabukuro K., Shirono K., Sakata H., Taguchi M., et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988, 29(6):1066-1077.
21. Madsen M.T., Park C.H., Thakur M.L. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 1988, 29(6):1038-1044.
22. Nakamura H., Hashimoto T., Oi H., Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989, 170(3 Pt 1):783-786.
23. Andreana L., Kudo M., Hatanaka K., Chung H., Minami Y., Maekawa K., et al. Contrast-enhanced ultrasound techniques for guiding and assessing response to locoregional treatments for hepatocellular carcinoma. Oncology 2010, 78(Suppl 1):68-77.
24. Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T. Posttreatment imaging of liver tumours. Cancer Imaging 2007;7 Spec No A:S28-36.
25. Jouneau S, Vauléon E, Caulet-Maugendre S, Polard E, Volatron AC, Meunier C, Tattevin P, Montani D, Garin E, Raoul JL, Delaval P. 131I-Labeled Lipiodol-Induced Interstitial Pneumonia: A Series of 15 Cases. Chest. in press.
26. Lambert B., Bacher K., Defreyne L. Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. Q J Nucl Med Mol Imaging 2009, 53(3):305-310.
27. Boschi A., Uccelli L., Duatti A., Colamussi P., Cittanti C., Filice A., et al. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004, 25(7):691-699.
28. Garin E., Noiret N., Malbert C., Lepareur N., Roucoux A., Caulet-Maugendre S., et al. Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs. Eur J Nucl Med Mol Imaging 2004, 31(4):542-546.
29. Liepe K., Brogsitter C., Leonhard J., Wunderlich G., Hliscs R., Pinkert J., et al. Feasibility of high activity rhenium-188- microsphere in hepatic radioembolization. Jpn J Clin Oncol 2007, 37(12):942-950.
30. Murthy R., Nunez R., Szklaruk J., Erwin W., Madoff D.C., Gupta S., et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, tecnica considerations, and potential complications. Radiographics 2005, 25(Suppl 1):S41-S55.
31. Pöpperl G., Helmberger T., Münzing W., Schmid R., Jacobs T.F., Tatsch K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm 2005, 20(2):200-208.
32. Tsochatzis E.A., Germani G., Burroughs A.K. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010, 37(2):89-93.
33. Burroughs AK, Andreana L, Isgrò G. Essentials in Interventional Oncology (Proceedings of the European Congress of Interventional Oncology 2010); Next Publishing Media & Research:78-87.
34. Marelli L., Shusang V., Buscombe J.R., Cholongitas E., Stigliano R., Davies N., et al. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009, 50(6):871-877.
35. Raoul J.I., Bretagne J.F., Caucanas J.P., Pariente E.A., Boyer J., Paris J.C., et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol. Cancer 1992, 69(2):346-352.
36. Raoul J.L., Guyader D., Bretagne J.F., Duvauferrier R., Bourguet P., Bekhechi D., et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994, 35(11):1782-1787.
37. Raoul J.L., Guyader D., Bretagne J.F., Heautot J.F., Duvauferrier R., Bourguet P., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26(5):1156-1161.
38. Bhattacharya S., Novell J.R., Dusheiko G.M., Hilson A.J., Dick R., Hobbs K.E. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995, 76(11):2202-2210.
39. Lammer J., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A., et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33(1):41-52.
40. Kumar A., Srivastava D.N., Chau T.T., Long H.D., Bal C., Chandra P., et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment-prospective multi center clinical trial. Radiology 2007, 243(2):509-519.
41. Garin E., Rakotonirina H., Lejeune F., Denizot B., Roux J., Noiret N., et al. Effect of a 188 Re-SSS lipiodol/131Ilipiodol mixture, 188 Re-SSS lipiodol alone or 131I-lipiodol alone on the survival of rats with hepatocellular carcinoma. Nucl Med Commun 2006, 27(4):363-369.
42. Steel J., Baum A., Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90- Yttrium microspheres (Therasphere). Psychooncology 2004, 13(2):73-79.
43. D'Avola D, Iñarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero I, Quiroga J, Prieto J, Sangro B. Extended survival in patients with unresectable advanced hepatocellular carcinoma treated using radioembolizationILCA (The International Liver Cancer Association), Annual Conference 2008. Book of Abstracts: Abstract P-139.
44. Moreno Luna LE, Sanchez W, James AC, Wiseman GA, Roberts LR. Survival of patients treated with Yttrium-90 radioembolisation vs chemoembolisation for unresectable hepatocellular carcinoma. ILCA (The International Liver Cancer Association), Annual Conference 2009. Book of Abstracts: Abstract O-033.
45. Khanna V, Dhanasekaran R, Kooby DA, Delman KA, Staley CA, Kauh JS, Carew JD, Kim HS. Comparision of survival benefits of conventional TACE, Precision TACE (Drug Eluting Beads with Doxorubicin) and Yttrium-90 Radioembolization (SIR-Spheres) for unresectable HCC. SIR (Society of Interventional Radiology), Annual Scientific Meeting 2009. J Vasc Interv Radiol 2009;26(2S):S84. Abstract 217.
46. Scanlon T, Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Mulcahy MF, Sato KT, Omary R, Salem R. Treatment of solitary HCC: comparison of TACE and Y90 radioembolization. SIR (Society of Interventional Radiology), Annual Scientific Meeting 2009. J Vasc Interv Radiol 2009;26(2S):S75. Abstract 195.
47. Riaz A, Lewandowski JR, Ryu RK, Kulik L, Mulcahy MF, Abecassis M, Sato KT, Omary RA, Salem R. Chemoembolization vs radioembolization: comparison of toxicity, imaging response and long-term outcomes in 100 TACE vs 104 Y90 patients. SIR (Society of Interventional Radiology), Annual Scientific Meeting 2009. J Vasc Interv Radiol 2009;26(2S):S83. Abstract 215.
48. Woodall C.E., Scoggins C.R., Ellis S.F., Tatum C.M., Hahl M.J., Ravindra K.V., et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis. J Am Coll Surg 2009, 208(3):375-382.
49. Vente M.A., Wondergem M., van der Tweel I., van den Bosch M.A., Zonnenberg B.A., Lam M.G., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19(4):951-959.
50. Iñarrairaegui M, Thurston KT, Martinez-Cuesta A, Bilbao JI, Arbizu J, Sangro B Radioembolization of hepatocellular carcinoma in patients presenting with portal vein occlusion: a safety analysis. ILCA (the International Liver Cancer Association), Annual Conference 2008. Book of Abstracts: Abstract P-140.
51. Sato K., Lewandowski R.J., Bui J.T., Omary R., Hunter R.D., Kulik L., et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006, 29(4):522-529.
52. Saar B., Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int 2008, 28(2):189-199.
53. Kulik L.M., Carr B.I., Mulcahy M.F., Lewandowski R.J., Atassi B., Ryu R.K., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47(1):71-81.
54. Salem R., Lewandowski R.J., Kulik L., Wang E., Riaz A., Ryu R.K., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140(2):497-507.
55. Bruix J. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
56. Beaugrand M., N'kontchou G., Seror O., Ganne N., Trinchet J.C. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):201-211.
57. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
58. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699.
59. Jonas S., Bechstein W.O., Steinmüller T., Herrmann M., Radke C., Berg T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33(5):1080-1086.
60. Andreana L., Burroughs A.K. Treatment of early hepatocellular carcinoma: How to predict and prevent recurrence. Dig Liver Dis 2010, 42(Suppl 3):S249-S257.
61. Miyayama S., Matsui O., Yamashiro M., Ryu Y., Takata H., Takeda T., et al. Iodized oil accumulation in the hypovascular tumor portion of early-stage hepatocellular carcinoma after ultraselective transcatheter arterial chemoembolization. Hepatol Int 2007, 1(4):451-459.
62. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353(9155):797-801.
63. Lau W.Y., Lai E.C., Leung T.W., Yu S.C. Adjuvant intra-arterial iodine-131- labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008, 247(1):43-48.
64. Ng K.M., Niu R., Yan T.D., Zhao J., McKay E., Chu F.C., et al. Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford) 2008, 10(6):388-395.
65. Partensky C., Sassolas G., Henry L., Paliard P., Maddern G.J. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000, 135(11):1298-1300.
66. Boucher E., Corbinais S., Rolland Y., Bourguet P., Guyader D., Boudjema K., et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003, 38(5):1237-1241.
67. Raoul J.L., Messner M., Boucher E., Bretagne J.F., Campion J.P., Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg 2003, 90(11):1379-1383.
68. Tabone M., Vigano' L., Ferrero A., Pellerito R., Carbonatto P., Capussotti L. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 2007, 33(1):61-66.
69. Kulik L.M., Atassi B., van Holsbeeck L., Souman T., Lewandowski R.J., Mulcahy M.F., et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006, 94(7):572-586.
70. Chung Y.L., Jian J.J., Cheng S.H., Tsai S.Y., Chuang V.P., Soong T., et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12(9):2706-2715.
71. Wang B., Xu H., Gao Z.Q., Ning H.F., Sun Y.Q., Cao G.W. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008, 49(5):523-529.
72. Shim J.H., Park J.W., Kim J.H., An M., Kong S.Y., Nam B.H., et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008, 99(10):2037-2044.
73. Horgan AM, Dawson LA, Swaminath A, Knox JJ. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J Gastrointest Cancer in press.